SporesBiotics Formula combines 3 probiotic strains in spore form: Bacillus clausii, Bacillus subtilis and Bacillus coagulans, at a dose of 10 billion CFU per day.
Protected by their spore coat, these probiotics survive particularly well in the stomach and work synergistically in the gut, the centre of the immune system.
The SporesBiotics Formula probiotic supplement is classified in our product category dedicated to gastrointestinal health.
Benefits of Bacillus clausii, subtilis and coagulans spore probiotics
The three probiotic strains contained in SporesBiotics Formula support the balance of the intestinal microbiota.
The latter is essential for maintaining intestinal health and comfort, as well as the immune system.
These spore-forming probiotics, all three from the famous Bacillus family, are:
-
Bacillus clausii (also known as Alkalihalobacillus clausii), which is particularly valued for helping to restore the microbiota after disturbances such as those caused by antibiotic treatments. In addition, its remarkable resistance to antibiotics makes it valuable for preventing imbalances. Researchers are also investigating its potential role in modulating the immune response, which could reduce excessive intestinal reactivity (1-4);
-
Bacillus subtilis, which is being studied for its possible antibacterial properties, making it ideal for helping to inhibit the growth of pathogens. Numerous studies also highlight the potential of Bacillus subtilis to stimulate certain defence mechanisms in the gut (5-6); and
-
Bacillus coagulans (also known as Heyndrickxia coagulans), which current studies suggest promotes the production of digestive enzymes and organic acids, thereby improving nutrient absorption. This probiotic is often recommended by naturopaths to help overcome digestive disorders such as bloating and irregular bowel movements (7-9).
4 key benefits of the SporesBiotics Formula probiotic synergy
SporesBiotics Formula has 4 key benefits:
-
Resistant spore probiotics: the spores used correspond to a natural survival form of certain microorganisms, recognisable by their protective shells. These robust spore envelopes greatly enhance the probiotics' ability to survive in the digestive tract (particularly when passing through the stomach, which is a highly acidic environment) and to establish themselves effectively in the intestine. More resistant to heat, probiotics in spore form also offer greater stability within the capsules, without the need for refrigeration.
-
Exclusive synergy targeting the gut and immunity: the three strains of Bacillus have been specifically selected for their complementary properties and documented benefits for the gut and immune system. It is this combination that gives our formula its unique character and remarkable effectiveness.
-
Powerful dosage: this multi-strain supplement provides you with 10 billion CFUs per day (i.e. 2.5 billion CFUs of Bacillus clausii, 3.75 billion CFUs of Bacillus subtilis and 3.75 billion CFUs of Bacillus coagulans for 2 capsules daily).
-
Gastro-resistant capsules: SporesBiotics Formula comes in capsules that are resistant to stomach acid, which further increases the viability of the probiotics ingested and ensures their optimal release in the intestine.
Daily dose: 2 capsules
Number of doses per box: 30
|
Daily dose
|
Bacillus subtilis LMGS 31763
|
3.75 × 10⁹ CFU
|
Bacillus coagulans (Heyndrickxia coagulans) LMGS 30832
|
3.75 × 10⁹ CFU
|
Bacillus clausii (Alkalihalobacillus clausii) UBCC07
|
2.5 × 10⁹ CFU
|
Other ingredients: hypromellose capsule, acacia gum.
|
Recommended amount:
Take 2 capsules per day, 30 minutes before meals.
Each capsule contains 5 billion probiotics.
Duration: 30 days.
Storage: store in a cool, dry place away from heat, light and humidity.
Watch out: as with any dietary supplement, consult a healthcare professional before use if you are pregnant, breastfeeding or have a health condition.
Precautions: for adults. Do not exceed the recommended daily dose. This product is a dietary supplement and should not be used as a substitute for a varied and balanced diet or a healthy lifestyle. Keep out of reach of young children.
- Abbrescia A, Palese LL, Papa S, Gaballo A, Alifano P, Sardanelli AM. Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation. Curr Med Chem. 2014 Dec;1(2):102–10. doi: 10.2174/2212707002666150128195631. Epub 2014 Dec. PMCID: PMC5388794.
- Ahire JJ, Kashikar MS, Madempudi RS. Survival and Germination of Bacillus clausii UBBC07 Spores in in vitro Human Gastrointestinal Tract Simulation Model and Evaluation of Clausin Production. Front Microbiol. 2020 Jun 10;11:1010. doi: 10.3389/fmicb.2020.01010. PMID: 32733389; PMCID: PMC7358638.
- E. Ghelardi, F. Celandroni, S. Salvetti, S.A. Gueye, A. Lupetti, S. Senesi, Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore‐based probiotic formulation, Journal of Applied Microbiology, Volume 119, Issue 2, 1 August 2015, Pages 552–559, https://doi.org/10.1111/jam.12848
- Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1181-8. doi: 10.1111/j.1365-2036.2004.02274.x. PMID: 15569121.
- Nannan C, Vu HQ, Gillis A, Caulier S, Nguyen TTT, Mahillon J. Bacilysin within the Bacillus subtilis group: gene prevalence versus antagonistic activity against Gram-negative foodborne pathogens. J Biotechnol. 2021 Feb 10;327:28-35. doi: 10.1016/j.jbiotec.2020.12.017. Epub 2020 Dec 30. PMID: 33387595.
- Bóka, B., Manczinger, L., Kocsubé, S. et al. Genome analysis of a Bacillus subtilis strain reveals genetic mutations determining biocontrol properties. World J Microbiol Biotechnol 35, 52 (2019). https://doi.org/10.1007/s11274-019-2625-x
- Kallur RK, Madapati S, Mathur A, Bhattacharya S. The role of Weizmannia (Bacillus) coagulans LMG S-31876 in treating IBS-diarrhea. Front Nutr. 2024 Feb 5;10:1310462. doi: 10.3389/fnut.2023.1310462. PMID: 38375355; PMCID: PMC10875997.
- Skrzydło-Radomańska B, Prozorow-Król B, Kurzeja-Mirosław A, Cichoż-Lach H, Laskowska K, Majsiak E, Bierła JB, Agnieszka S, Cukrowska B. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. J Clin Med. 2023 Jul 22;12(14):4838. doi: 10.3390/jcm12144838. PMID: 37510953; PMCID: PMC10381776.
- Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (Baltimore). 2021 Jan 22;100(3):e23641. doi: 10.1097/MD.0000000000023641. PMID: 33545934; PMCID: PMC7837859.